Benefit of PSA reduced by loss of quality-adjusted life-years

Benefit of PSA reduced by loss of quality-adjusted life-years
Although the European Randomized Study of Screening for Prostate Cancer has reported a 29 percent reduction in prostate-cancer mortality for men who undergo prostate-specific antigen screening, the benefit is attenuated by loss of quality-adjusted life-years due to post-diagnosis effects, according to a study published in the Aug. 16 issue of the New England Journal of Medicine.

(HealthDay) -- Although the European Randomized Study of Screening for Prostate Cancer (ERSPC) has reported a 29 percent reduction in prostate-cancer mortality for men who undergo prostate-specific antigen (PSA) screening, the benefit is attenuated by loss of quality-adjusted life-years (QALYs) due to post-diagnosis effects, according to a study published in the Aug. 16 issue of the New England Journal of Medicine.

Eveline A.M. Heijnsdijk, Ph.D., from the Erasmus Medical Center in Rotterdam, Netherlands, and colleagues predicted the number of prostate cancers, treatments, deaths, and QALYs gained following the introduction of PSA screening using Microsimulation Screening Analysis of ERSPC follow-up data.

The researchers found that, for each 1,000 men followed for their entire life span, annual screening between age 55 and 69 years was predicted to result in a 28 percent reduction in (nine fewer deaths), a 35 percent reduction in palliative therapy (14 fewer cases), and a total of 73 life-years gained. Fifty-six QALYs were gained, which was a reduction of 23 percent from the unadjusted life-years gained. Ninety-eight men would need to be screened and five cancers detected to prevent one death. Screening of all men aged 55 to 74 would result in 82 life-years gained but would still result in 56 QALYs.

"The benefit of PSA screening was diminished by loss of QALYs owing to post-diagnosis long-term effects," the authors write. "Longer follow-up data from both the ERSPC and quality-of-life analyses are essential before universal recommendations regarding screening can be made."

Beckman Coulter partially funded the study; several authors disclosed to the pharmaceutical industry and Beckman Coulter.

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

PSA screening cuts deaths by 20 percent

Mar 18, 2009

Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) published online 1700 hours CET, today 18 March (NEJM, Online First*). ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

PeterD
1 / 5 (1) Aug 17, 2012
Only and idiot would have a PSA done.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.